Navigation Links
BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
Date:4/8/2008

ut Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with Bristol-Myers Squibb, and the discovery and development of drugs for prevention and treatment of cardiovascular disease and high cholesterol including the newly selected development candidate. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trad
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
6. EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
9. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
10. Bristol-Myers Squibb Announces Dividend
11. Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... USC have developed a new microscopy technology that ... animals at higher-than-ever resolution. , Dubbed "Complementation Activated ... resolutions that are an order of magnitude finer ... the behavior of biomolecules at the nanometer scale. ... by Nature Communications , the researchers behind ...
(Date:9/18/2014)... City, MX (PRWEB) September 18, 2014 ... in Mexico City, MX. ASEA is the manufacturer of ... and the skin care product, RENU28. , The ... Regional Vice President Duvan Botero, and ASEA Field Leader ... Samuelson holds a PhD in Atomic/Medical Physics from the ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2
... Corporation,(Nasdaq: VOLC ) today announced that it will ... of fiscal 2007 on Tuesday, February 12., The ... financial,results and operating activities open to all interested parties ... Time), Tuesday, February,12, hosted by Scott Huennekens, president and ...
... Begin at ProHEALTH Facility by End of First Quarter, ... NBS ),which is pioneering the pre-disease collection, processing ... need, today announced,receipt of a provisional license for comprehensive ... from the New York State,Department of Health for the ...
... - Three New Board Members to Form Audit ... 5 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, Inc. ("China Pharma") ... generic and brand,bio-pharmaceutical products in China, today announced ... Baowen Dong to its Board of Directors,forming the ...
Cached Biology Technology:Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2NeoStem Announces NY State License for Adult Stem Cell Collection 2NeoStem Announces NY State License for Adult Stem Cell Collection 3China Pharma Appoints Three Independent Non-Executive Directors 2China Pharma Appoints Three Independent Non-Executive Directors 3
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3Mellon Foundation awards grant for major project in the humanities and sciences 2
... April 22, 2012) Researchers at Columbia University Medical ... the retention and release of the brain,s stem cells. ... neurologic development and could eventually lead to regenerative therapies ... collaborative effort of the laboratories of Drs. Anna Lasorella ...
... reductions in salt content and taxation on products containing salt ... each year from cardiovascular disease (CVD) by 2-3 per cent ... World Congress of Cardiology are the first findings from a ... year. The study set out to assess ...
... the Florida campus of The Scripps Research Institute has been ... Health to develop a range of new tests that could ... degenerative disorders of advancing age. Shuji Kishi, an assistant ... three-year study. The new tests will focus on diseases ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Tax on salt could reduce cardiovascular disease deaths by 3 percent 2Researcher awarded $1 million for stress-associated disease and aging research 2
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: